» Articles » PMID: 38228835

Intra-tumoral T Cells in Pediatric Brain Tumors Display Clonal Expansion and Effector Properties

Abstract

Brain tumors in children are a devastating disease in a high proportion of patients. Owing to inconsistent results in clinical trials in unstratified patients, the role of immunotherapy remains unclear. We performed an in-depth survey of the single-cell transcriptomes and clonal relationship of intra-tumoral T cells from children with brain tumors. Our results demonstrate that a large fraction of T cells in the tumor tissue are clonally expanded with the potential to recognize tumor antigens. Such clonally expanded T cells display enrichment of transcripts linked to effector function, tissue residency, immune checkpoints and signatures of neoantigen-specific T cells and immunotherapy response. We identify neoantigens in pediatric brain tumors and show that neoantigen-specific T cell gene signatures are linked to better survival outcomes. Notably, among the patients in our cohort, we observe substantial heterogeneity in the degree of clonal expansion and magnitude of T cell response. Our findings suggest that characterization of intra-tumoral T cell responses may enable selection of patients for immunotherapy, an approach that requires prospective validation in clinical trials.

Citing Articles

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.

Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney A, Arnett A Nature. 2024; 637(8047):940-946.

PMID: 39604730 DOI: 10.1038/s41586-024-08261-8.


Cranioencephalic functional lymphoid units in glioblastoma.

Dobersalske C, Rauschenbach L, Hua Y, Berliner C, Steinbach A, Gruneboom A Nat Med. 2024; 30(10):2947-2956.

PMID: 39085419 PMC: 11485206. DOI: 10.1038/s41591-024-03152-x.


Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade.

von Roemeling C, Patel J, Carpenter S, Yegorov O, Yang C, Bhatia A Nat Commun. 2024; 15(1):5871.

PMID: 38997283 PMC: 11245621. DOI: 10.1038/s41467-024-49989-1.


Immune Microenvironment in Childhood Cancers: Characteristics and Therapeutic Challenges.

Pathania A Cancers (Basel). 2024; 16(12).

PMID: 38927907 PMC: 11201451. DOI: 10.3390/cancers16122201.

References
1.
Pollack I . Brain tumors in children. N Engl J Med. 1994; 331(22):1500-7. DOI: 10.1056/NEJM199412013312207. View

2.
Chevignard M, Camara-Costa H, Doz F, Dellatolas G . Core deficits and quality of survival after childhood medulloblastoma: a review. Neurooncol Pract. 2019; 4(2):82-97. PMC: 6655396. DOI: 10.1093/nop/npw013. View

3.
Makale M, McDonald C, Hattangadi-Gluth J, Kesari S . Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol. 2016; 13(1):52-64. PMC: 5805381. DOI: 10.1038/nrneurol.2016.185. View

4.
Hwang E, Sayour E, Flores C, Grant G, Wechsler-Reya R, Hoang-Minh L . The current landscape of immunotherapy for pediatric brain tumors. Nat Cancer. 2022; 3(1):11-24. DOI: 10.1038/s43018-021-00319-0. View

5.
Dunkel I, Doz F, Foreman N, Hargrave D, Lassaletta A, Andre N . Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol. 2023; 25(8):1530-1545. PMC: 10398811. DOI: 10.1093/neuonc/noad031. View